{
  "report_rows": [
    {
      "kpi": "Adjusted EPS",
      "prediction": "IN-LINE",
      "answer": "pred ~$2.27 vs. cons $2.26",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Net sales",
      "prediction": "IN-LINE",
      "answer": "pred ~$4.40B vs. cons $4.37B",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Organic sales growth",
      "prediction": "BEAT",
      "answer": "pred ~1.5% vs. cons 1.3%",
      "confidence": "LOW"
    }
  ],
  "guide_rows": [
    {
      "kpi": "Full-year adjusted EPS",
      "prediction": "LOWER",
      "answer": "guide ~$7.90 midpoint vs. cons $7.93 (FY2026)",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Adjusted EPS",
      "prediction": "LOWER",
      "answer": "guide ~$2.14 vs. cons $2.19 (Q3 2026)",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Organic sales growth",
      "prediction": "UNCHANGED",
      "answer": "guide ~2.0% vs. cons 2.0% (Q3 2026)",
      "confidence": "LOW"
    }
  ],
  "day1_residual_pct": -2.5,
  "day1_confidence": "MEDIUM",
  "day5_residual_pct": -3.8,
  "day5_path": "FOLLOW-THROUGH",
  "day5_rationale": "A broadly in-line Q2 is outweighed by price-cost pressure and Q3 adjusted EPS guidance of ~$2.14 versus consensus of $2.19; the implied second-half earnings path pulls FY2026 estimates from consensus near $7.93 toward the ~$7.90 guidance midpoint, sustaining negative revisions after day 1.",
  "day5_confidence": "MEDIUM"
}